Hyperion rises 13.4% on Ravicti data publication
This article was originally published in Scrip
Executive Summary
Hyperion Therapeutics ended the day at a new high on 25 February, gaining 13.4% to close at $31.41 per share based on newly published data for Ravicti (glycerol phenylbutyrate) in the treatment of hepatic encephalopathy (HE) and the company's Phase III update.
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.
Ipsen Expands Its Rare Neurological Disease Pipeline With Skyhawk Deal
Deal Snapshot: Ipsen committed up to $1.8bn in upfront and milestone fees to develop novel treatments for rare neurological diseases with Skyhawk’s RNA-targeting small molecule platform.